Stocksigma LogoStocksigma Logo

IOL Chemicals Posts Record Q2 FY27 Results Driven by Margin Expansion

IOL Chemicals reported record standalone Q2 FY27 revenue of ₹795.0 Cr, up 40.1% YoY, with EBITDA surging 79.6% YoY to ₹114.9 Cr

IOL Chemicals Posts Record Q2 FY27 Results Driven by Margin Expansion

IOL Chemicals & Pharmaceuticals Ltd · Press Release · 31 Oct 2026, 1:37 am

IOL Chemicals Posts Record Q2 FY27 Results Driven by Margin Expansion IOL Chemicals reported record standalone Q2 FY27 revenue of ₹795.0 Cr, up 40.1% YoY, with EBITDA surging 79.6% YoY to ₹114.9 Cr. EBITDA margin expanded 321 bps YoY to 14.4%, supported by better product mix and operating efficiencies. PAT jumped 116.8% YoY to ₹65.0 Cr, with PAT margin rising 290 bps to 8.1%. Pharmaceuticals revenue reached ₹472.8 Cr, with non-Ibuprofen sales growing ~70% YoY to contribute 45% of segment revenue. Chemicals revenue rose to ₹322.3 Cr, driven by improved realisations.

Original exchange filing (PDF)

More announcements from IOL Chemicals & Pharmaceuticals Ltd

All IOL Chemicals & Pharmaceuticals Ltd announcements